Introduction
Despite this, very few markers have been approved for clinical use, and efforts to find new markers and to develop techniques for their discovery are ongoing. The lack of approved clinical There is a pressing clinical need for the discovery of effective biomarkers is a result of problems associated with their developbiomarkers for cancer. In particular, they are useful in the followment and validation. One major difficulty is that markers exing ways: to diagnose a disease (particularly for early detection or pressed in tumors may also be seen in normal/healthy tissue or in diagnosis of occult tumors); to aid in staging; to predict the other disease states, albeit at different levels of expression. An outcome of a disease; to act as a surrogate for clinical progression; example of this is the acute-phase protein serum amyloid A. High or, to monitor responses to treatment. Such biomarkers are useful levels of amyloid A are associated with a number of cancers, but where patient stratification prior to treatment can considerably levels are also elevated in other inflammatory diseases. [1] [2] [3] Furimprove the outcome of clinical trials.
thermore, biomarkers must be validated in clinical trials with sufficient numbers of patients/samples for statistical significance syngeneic or allogeneic, and both cases rely on the generation of to be reached, and must be repeatable by multiple groups using immunity to antigens shared between the vaccine and the patient's standardized methodologies. Consequently, although many proown tumor. Dendritic cells take up antigens in different forms and spective biomarkers now exist, few have been validated for use in present them to T cells. This often involves pulsing the dendritic cancer. A huge volume of literature exists relating to the identificells ex vivo with peptide, protein, or with tumor lysate or mRNA cation of novel cancer biomarkers, which is beyond the scope of taken from the patient. this review. Here, we will concentrate on those biomarkers related All of these approaches may elicit cellular and/or humoral specifically to prediction of outcome, monitoring of efficacy, or immune responses, although dendritic cell therapy is biased tothose which may ultimately be used as endpoints in a cancer wards the generation of a cellular response. Although responses to vaccine/immunotherapy setting (see table I and table II [18] being, tested in clinical trials has been extensively reviewed elsedetects the presence of a T-cell receptor specific for a defined where and a detailed description of these strategies is beyond the MHC-peptide complex using fluorescence-activated cell scanning scope of this article. Briefly, cancer vaccines fall into the follow-(FACS)-based technology. T-cell proliferation assays may be used ing three broad categories: (i) protein/peptide vaccines; (ii) DNA to assess the capacity of T-cell populations to expand in response vaccines; and (iii) cellular vaccines.
to a known antigen and cytotoxic T lymphocyte (CTL) assays [19] Protein/peptide vaccines are the most widely tested of all measure direct killing of tumor cells or peptide pulsed surrogates. cancer vaccines and are composed of a protein or peptide that is Most clinical trials also incorporate the measurement of cytokine tumor specific or over expressed in tumor tissue, relative to normal profiles (by ELISA, ELISPOT, intracellular FACS, and multiplex tissue.
[13] Typically, in the case of peptide vaccines, these are cytokine assays), which give an indication of the pro-or antirestricted only to patients of a particular HLA type.
inflammatory nature of the response. [20] In particular, multiplex DNA vaccines are composed of cDNA sequences, again reprecytokine assays have expanded the capacity to measure multiple senting tumor-specific epitopes, engineered into plasmid or viral cytokines simultaneously from small samples. [21, 22] Finally, anvectors under the control of strong transcriptional promoters. [14, 15] tibody responses to defined antigens can be measured, generally These express tumor proteins when injected into tissue (usually by ELISA. Often, there is no consensus about which techniques muscle).
provide the best readout for vaccines and, to date, little evidence Cellular vaccines encompass a range of available techniques, exists to directly correlate immunological response with clinical including injection with whole irradiated tumor cells [16] or with outcome. A further complication is that little is known about the autologous dendritic cells.
[17] Whole tumor cells may either be sured as a means of monitoring immune responses to vaccines. A immunological status of patients before treatment, which may number of recent papers support the idea that the presence of a affect their ability to respond to vaccination. Here, we set out DTH response is correlated with a positive clinical outcome in immunological parameters that have been shown to relate to metastatic melanoma (table I) . [4] [5] [6] However, such correlations are clinical response and which may prove to be important biomarkers not always observed and the relationship between DTH and an for the development of effective vaccine strategies.
effective anti-tumor response still requires clarification. In one such study, de Vries et al., [7] although unable to correlate DTH
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with outcome, were able to show that biopsies of DTH sites contained tumor-antigen specific CD8+ T cells and that the presOne major obstacle to the development of immunological ence of such antigen-specific DTH infiltrating T cells correlated biomarkers is that it is not clear what constitutes an effective antiwith increased survival. The use of DTH to monitor anti-tumor tumor immune response. Therefore, in most clinical trials a wide responses is controversial, and more data are required to clarify range of immunological parameters (see section 2) are measured why some studies show positive correlations with clinical outcome in the hope that some will correlate with clinical outcome.
while others do not.
A refinement of crude DTH activity is to examine the presence
T-Cell Responses
of tumor infiltrating lymphocytes (TILs), which may be of prognostic value. Studies in stage III/IV melanoma, [8] ovarian canThere is compelling evidence that T-cell responses play an cer, [26, 27] and glioblastoma multiforme [28] demonstrated better important role in mounting an effective anti-tumor response. Conoverall survival in patients whose tumors contained a strong T-cell sequently, several approaches are used to measure the specificity infiltrate. In two of these studies, the infiltrating cells were CD8+ and magnitude of the response of T cells circulating in the periph-T cells, suggesting that cytolytic cells may be important in antieral blood after vaccination.
[20] The very nature of the techniques tumor responses. Haanen et al. [6] correlated improved overall for measuring T-cell responses must assume some knowledge of survival of metastatic melanoma patients with the presence of the peptide or MHC specificity of the responding cells. However, antigen-specific TILs detected by MHC class I tetramers. in cases where the immunological readout depends on peptide specificity, the effect of epitope spread (i.e. spreading of the T-cell T-regulatory cells (T reg ) are also found as infiltrates in tumors. response beyond the immunizing epitope) will not be accounted Ablation of these cells, which are known to suppress immune for. [23] responses to tumors, is associated with improved anti-tumor CTL Loss of antigenicity/MHC class I expression by the tumor may responses. [29] Increased proportions of Treg TILs have been found make the measurement of specific T-cell responses an unreliable in non-small cell lung cancer, [30] pancreatic and breast cancer, [31] biomarker since the tumors become resistant to T-cell attack. and ovarian cancer. [27, 32] Moreover, the presence of high levels of However, the antigenic changes that make the measurement of T Treg in the tumor was correlated with poor survival, [32] while a high cells redundant may themselves provide predictive biomarkers.
CD8+/Treg ratio was associated with improved survival. [27] These Recently, attempts to define the nature of antigen escape by cells are likely to help maintain an immunosuppressive environcolorectal tumors led to the suggestion that low MHC class I ment in the tumor and consequently their presence in tumor expression was associated with reduced disease-specific survival biopsies may be predictors of poor response to vaccination. To in patients with early stage disease.
[24] Furthermore, in melanoma date, the screening of TILs has been limited to biopsies before it was shown that loss of antigenicity in metastases was correlated treatment and therefore may be of prognostic significance. Further with poor clinical responses, despite high levels of circulating work will be needed to determine whether such TILs can be antigen-specific T cells.
[25] Interestingly, van Houdt et al. [8] monitored through the course of the disease, for example through showed that in metastatic melanoma patients treated with autolofine-needle aspirates of metastatic lesions.
Cytokine Profiles
a fixed plastic substrate (as for ELISA), allow simultaneous measurement of a wide range of cytokines in one assay using a single sample. It is therefore possible that accurate, simultaneous meaIt is postulated, based largely on data from murine tumor surement of a range of cytokines will generate profiles indicating models, that a proinflammatory, T-helper type 1 (T h 1) response is the nature of the immune response, and which can be correlated most effective against tumors and is associated with tumor regreswith clinical responses to vaccination. sion. [33] [34] [35] [36] Proinflammatory responses are associated with a skewed expression of cytokines; typical Th1 cytokines are interfer-4. Autoimmunity on (IFN)-γ, interleukin (IL)-2, IL-12, and tumor necrosis factor-α, whereas T h2 responses are characterized by IL-4, IL-5, IL-10, and
Patients in clinical trials for immunotherapy are monitored for IL-13. Cytokines can be measured either in serum/plasma (where autoimmune toxicity associated with the therapy. Generally, they represent the combined cytokine expression of tissues, lymautoimmunity has been considered to be a downside of such phocytes, and the tumor itself) or as a secretory product of T cells.
therapeutic regimens, although in most cases cancer vaccines have The latter is usually measured ex vivo and in response to either an few worrying adverse effects. Paradoxically, in many cancers an antigen corresponding to that administered in the vaccine, or to a effective anti-tumor response requires the therapy to break tolerpolyclonal stimulus such as phorbol myristic acetate.
ance and risk the induction of autoimmunity. In three recent Serum cytokines, in particular IL-6, have been shown to correpapers, [11, 40, 41] the induction of autoimmunity through the adminislate with poor prognosis in a number of different cancers. [34, [37] [38] [39] tration of immunotherapeutic regimens correlated with clinical However, although cytokines are often measured in the sera of responses in metastatic melanoma. One study used gp100 peptide vaccinated patients, there have been few general correlations vaccination in combination with anti-CTLA4 monoclonal antibetween treatment outcome and changes in serum cytokine levels body therapy for 56 patients, 14 of whom experienced grade 3-4 in response to vaccination. The measurement of cytokines proautoimmune toxicity (affecting gastrointestinal tract, eyes, skin, duced by T cells has also been a poor biomarker for outcome in liver, and pituitary). [11] Five of these 14 patients showed evidence clinical trials, since patients who produce Th1 type responses to in of tumor regression, compared with only 2 of the 42 patients in vitro stimulation do not necessarily have better anti-tumor rewhom autoimmune toxicity was not seen (p = 0.008). There was sponses. [9] A recent notable exception is an article by Carbone et no correlation between the magnitude of the immune response and al., [9] who showed that peptide vaccinations tailored to patientthe clinical response. Toxicity was managed successfully and all specific mutations in tumor protein p53 or k-ras gave rise to CTL patients in this study remained well. Given the recent experience responses and that IFNγ production by in vitro-stimulated T cells gained from the TGN1412 trial, [42] induction of autoimmunity correlated with increased median survival times. It is noteworthy should be regarded with caution. However, with careful monitorthat many clinical trials do not attempt such correlations and that ing and management, autoimmunity may not be as undesirable as negative correlations often go unreported.
previously thought and may be a credible biomarker for monitorIn one study, [10] the lack of an obvious correlation between ing the effects of immunotherapeutic intervention. clinical response and immunological response was overcome by using an artificial neural network (ANN) [see section 6] to discern 5. Predictors of Response to Immunotherapy patterns within their data that were not immediately apparent using classical statistical analysis. In this study [10] of prostate cancer Although many biomarkers exist that may be used to predict the patients vaccinated with an allogeneic tumor cell vaccine, positive outcome of therapy, to date, very few have been clinically validatprostate-specific antigen velocity responses correlated with a Th1 ed. Outside the use of immunological monitoring for T-cell and profile, whereas non-responding patients had a mixed Th1/Th2 cytokine responses, very little research appears to be available to profile. Such multiparametric analysis may be of use in extracting determine biomarkers that specifically predict the response to relevant information from complex datasets in order to demonimmunotherapy (see table II) . One exception to this is a recent strate the use of cytokine profiling for immunological monitoring. study where patients with metastatic melanoma were treated with Improvements in high-throughput technology are likely to the cancer vaccine Canvaxin ® 1 (a mixture of irradiated melanoma change this situation. Multiplex cytokine assays have been develcell lines). [12] In this study, low expression levels of the apoptosis oped as a fusion of ELISA and FACS technologies. [21, 22] These inhibitor survivin in tumour tissue (as assessed by quantitative assays, which use beads to capture the analyte instead of binding to real-time PCR) were found to correlate with overall survival in a group of patients who received Canvaxin ® post-operatively. Phase it should be possible to use microarray profiling of tumors to I and II trials of Canvaxin ® showed a great deal of promise.
identify profiles useful for stratification of patients according to However, in phase III trials Canvaxin ® was ultimately unsuccesstheir capacity to respond to vaccination. ful in showing a difference between treatment and control arms of A number of proteomic techniques (e.g. surface-enhanced laser the study. It is interesting to speculate whether the use of survivin desorption ionization [SELDI] and matrix-assisted laser desorpto stratify patients in the phase III setting might have made a tion ionization [MALDI]-time of flight [TOF] mass spectrometry) difference to these data. There is great need for such markers to are available, which, like microarray technology, generate molecstratify patients into responder and non-responder groups prior to ular profiles of cancers (see review by Stroncek et al. [54] ). SELDIvaccination.
TOF uses the sequential binding of proteins to a microarray, according to biochemical characteristics (e.g. cation or anion 6. Multiple Biomarkers: The Way of the Future? exchange), and subsequent elution of whole proteins for mass spectrometry. In a similar way, MALDI-TOF involves binding of There are many good biomarkers for cancer that are used by proteins to a matrix and subsequent enzymatic digest and mass clinicians, but that have not necessarily been validated for use in spectrometry. Generally, such techniques take protein from accesclinical trials. These include α-feto protein and human chorionic sible tumor tissue or from serum. The latter is a good medium in gonadotropin (chorionic and testicular cancers); [43] CA-125 (ovawhich to look for biomarkers as its constitution is influenced by rian cancer); [44] CA19.9 (pancreatic cancer); [45] carcinoembryonal the tissues through which it passes and there is evidence that antigen (colorectal cancer); [46] and prostate-specific antigen (prostumors influence the proteomic profile of blood. Although protetate cancer).
[47] However, the sensitivity and specificity of tests omics has been used extensively to look for biomarkers in cancer, using such biomarkers can often be improved by combination with there is a paucity of data on changes in protein profiles in response other prognostic variables. For example, CA-125 is not approved to immunotherapy. However, it should be possible to detect for diagnostic screening in early ovarian cancer. The combination changes in tumor markers in response to therapy. As this technoloof three other protein markers (transthyretin, apolipoprotein A1, gy becomes more widespread the application to an immunotherand a cleavage fragment of inter-α-trypsin inhibitor heavy chain) apeutic setting is inevitable. with CA-125 improved the sensitivity of screening compared with Analysis of complex data derived from either immunological CA-125 alone. [48] analysis of samples from clinical trials or of mass spectrometry Recent advances in high-throughput analysis of tissue or serum and protein expression data from tumor tissue can be achieved has allowed the identification of protein or gene expression using ANN. [55] ANN has been devised to enable decisions, based 'profiles', which have greater prognostic value than single on experience, to be collated and thus allow a computer to discern biomarkers alone. Although a comprehensive review of highpatterns in very complex sets of data. To achieve this, the network throughput methods is beyond the scope of this review, a couple of must go through the following three stages: (i) training; (ii) validatechniques that are now in common use are worthy of mention.
tion; and (iii) pattern recognition. In order to train a network, data Probably the two most widely used high-throughput techniques from at least two patient groups are taken and the ANN is allowed used in biomarker discovery are DNA/RNA microarray analysis to examine any correlation that may exist between the immunologand mass spectrometry.
ical data corresponding to each group and the disease phenotype. Microarray analysis is based on the binding of RNA extracted
The network can then be validated, using known clinical outfrom tumor tissue to a known nucleotide sequence library (DNA or comes, before finally allowing the ANN to examine raw data. At oligonucleotide). It can be used to identify genes whose expression this point, the outcome is a ranking of variables, ranging from the increases or decreases in a population of tumor samples compared most to the least predictive of a particular disease state. Using with a reference sample (usually normal tissue).
[49] This type of complex algorithms, it is then possible to define a subset of analysis has been used to generate expression profiles that differvariables, which, when used in combination, may be predictive of entiate between cancers of different lineage (e.g. between T-and a particular clinical outcome. Clearly, this should have benefit in B-cell acute lymphoblastic leukemia), [50] and to identify tumor clinical trials, since it may be possible to identify at an early stage 'proliferation' signatures [51] or gene expression signatures that can those patients who will ultimately benefit from a particular therbe correlated with patient outcome. [52] This technology was recentapy. It should be noted that the ANN only makes decisions based ly used to identify an expression profile of metastatic melanoma on data which it has previously seen and, therefore, as datasets lesions, taken before therapy, which predicted patient responses to increase in size so does the predictive power of the ANN. At no IL-2 immunotherapy. [53] The wider implication of this work is that 
